Russia Announces It Has Completed Human Trials Of New COVID-19 Vaccine

Russia Announces It Has Completed Human Trials Of New COVID-19 Vaccine

Russia Announces It Has Completed Human Trials Of New COVID-19 Vaccine

Three of the participants who received the highest dosage of the vaccine reported at least one "severe" side effect.

The Moderna vaccine uses genetic material from the virus, called mRNA, to prompt the immune system to fight the coronavirus. BioNTech SE and Pfizer Inc's Covid-19 vaccine candidate is expected to be ready by the end of 2020.

Vadim Tarasov, director of the Institute for Translational Medicine and Biotechnology, confirmed the news, according to a Sputnik News report. "We're encouraged by the number of sites we've already set up - scores and scores of sites around the country for the first couple of vaccine candidates for their clinical trials", the official added. AIIMS New Delhi, and AIIMS Patna will start the initial part of Human trials of the vaccine.

The researchers are expecting the results of the clinical trials by August or September and the vaccine on the market by October.

"Of course, there is an unprecedented effort to develop a vaccine, but I would be very surprised if we had a vaccine effective in 2021", he said in an interview.

According to reports, the Phase 3 trial Moderna will have 30,000 participants in the USA, where 50% of those will be given the vaccine at 100mg dose, and the other half will receive a placebo.

"To see us at this stage of clinical testing a mere five months after we selected our lead vaccine candidate to what was essentially a newly emerging global infectious disease threat is simply remarkable".

But some in the scientific community said they would reserve judgment until they saw the full results in peer-reviewed form.

Emory's study consisted of 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. The levels of those antibodies were similar to those in the upper range in patients who had recovered from coronavirus infections.

More than half of the participants had side effects, including fatigue, chills, headaches, muscle aches and pain at the injection site.

According to Newsweek, the Russian vaccine is one of 160 potential candidates being developed and tested globally.

Participants will be routinely checked for antibodies. At the moment, it can not be concluded if the vaccine has been cleared for phase one of a total of three clinical trial phases.

The advantage of this technology is that it bypasses the need to manufacture viral proteins in the lab, helping to ramp up mass production. "Efforts are being taken to ensure that not a single day is wasted for regulatory or approval objective, without compromising on the science, quality and ethics part of it", Bhargava further stated.

Related news



[an error occurred while processing the directive]